Lipocine (NASDAQ:LPCN) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research report released on Friday.

Lipocine Price Performance

Shares of LPCN stock opened at $4.84 on Friday. The firm has a market cap of $25.88 million, a PE ratio of -2.83 and a beta of 1.21. The company has a 50-day moving average of $4.58 and a two-hundred day moving average of $5.55. Lipocine has a 1-year low of $2.31 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The business had revenue of $0.09 million for the quarter. Sell-side analysts anticipate that Lipocine will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.